Ishita Gupta

Dr. Ishita Gupta

College of Medicine, QU Health, Qatar University
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AMAhmed Malki
Ahmed Malki
RERasha Abu ElRuz
Rasha Abu ElRuz
IGIshita Gupta
Ishita Gupta
IGIshita Gupta
Ishita Gupta
Semir VranicSemir Vranic
Semir Vranic
Ala-Eddin Al MoustafaAla-Eddin Al Moustafa
Ala-Eddin Al Moustafa
Colorectal cancer (CRC), the third most common type of cancer, is the second leading cause of cancer-related mortality rates worldwide. Although modern research was able to shed light on the pathogenesis of CRC and provide enhanced screening strategies, the prevalence of CRC is still on the rise. Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, analyzing signaling pathways involved in CRC metastasis is necessary to elucidate the underlying mechanism of CRC progression and pharmacotherapy. This review focused on target genes as well as various cellular signaling pathways including Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF, and JAKs/STAT3, which are associated with CRC progression and metastasis. Additionally, alternations in methylation patterns in relation with signaling pathways involved in regulating various cellular mechanisms such as cell cycle, transcription, apoptosis, and angiogenesis as well as invasion and metastasis were also reviewed. To date, understanding the genomic and epigenomic instability has identified candidate biomarkers that are validated for routine clinical use in CRC management. Nevertheless, better understanding of the onset and progression of CRC can aid in the development of early detection molecular markers and risk stratification methods to improve the clinical care of CRC patients.

1 January 2020 in Journal of Cancer
Verified
Journal Article
Open access
BRBalsam Rizeq
Balsam Rizeq
IGIshita Gupta
Ishita Gupta
JIJosephine Ilesanmi
Josephine Ilesanmi
MAMohammed AlSafran
Mohammed AlSafran
MRMizanur Rahman
Mizanur Rahman
Allal OuhtitAllal Ouhtit
Allal Ouhtit
Conventional therapies for cancer treatment have posed many challenges, including toxicity, multidrug resistance and economic expenses. In contrast, complementary alternative medicine (CAM), employing phytochemicals have recently received increased attention owing to their capability to modulate a myriad of molecular mechanisms with a less toxic effect. Increasing evidence from preclinical and clinical studies suggest that phytochemicals can favorably modulate several signaling pathways involved in cancer development and progression. Combinations of phytochemicals promote cell death, inhibit cell proliferation and invasion, sensitize cancerous cells, and boost the immune system, thus making them striking alternatives in cancer therapy. We previously investigated the effect of six phytochemicals (Indol-3-Carbinol, Resveratrol, C-phycocyanin, Isoflavone, Curcumin and Quercetin), at their bioavailable levels on breast cancer cell lines and were compared to primary cell lines over a period of 6 days. This study showed the compounds had a synergestic effect in inhibiting cell proliferation, reducing cellular migration and invasion, inducing both cell cycle arrest and apoptosis. Despite the vast number of basic science and preclinical cancer studies involving phytochemicals, the number of CAM clinical trials in cancer treatment still remains nascent. In this review, we summarize findings from preclinical and clinical studies, including our work involving use of phytochemicals, individually as well as in combination and further discuss the potential of these phytochemicals to pave way to integrate CAM in primary health care.

28 November 2012 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
YAYahya Al-Farsi
Yahya Al-Farsi
Mostafa WalyMostafa Waly
Mostafa Waly
MAMarwan M. Al-Sharbati
Marwan M. Al-Sharbati
MAMohammed A. Al-Shafaee
Mohammed A. Al-Shafaee
OAOmar A. Al-Farsi
Omar A. Al-Farsi
RDRichard C. Deth
Richard C. Deth

1 March 2013 in Nutrition
Verified
Journal Article
Closed access
YAYahya Al-Farsi
Yahya Al-Farsi
Mostafa WalyMostafa Waly
Mostafa Waly
RDRichard C. Deth
Richard C. Deth
MAMarwan M. Al-Sharbati
Marwan M. Al-Sharbati
MAMohamed Al-Shafaee
Mohamed Al-Shafaee
AOAllal Ouhtit
Allal Ouhtit

30 June 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
SASoumaya Allouch
Soumaya Allouch
AMAhmed Malki
Ahmed Malki
AAAsma Allouch
Asma Allouch
IGIshita Gupta
Ishita Gupta
Semir VranicSemir Vranic
Semir Vranic
Ala-Eddin Al MoustafaAla-Eddin Al Moustafa
Ala-Eddin Al Moustafa
Cervical cancer is the fourth most common malignancy in women worldwide and a leading cause of cancer-related mortality in developing countries. Important etiological factors in this cancer are high-risk human papillomaviruses (HPV), as roughly 96% of cervical cancer cases are positive for these oncoviruses. On the other hand, it has been recently pointed out that E6/E7 oncoproteins of high-risk HPV can upregulate the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) axis. Likewise, several recent reports showed that checkpoint blockades targeting PD-1/PD-L1 pathways have achieved efficient clinical responses via suppressing cancer progression and improving survival in several types of human cancers including metastatic cervical cancer. In this review, we summarize recent advances in our understanding of the PD-1/PD-L1 signaling pathway and its interaction with high-risk HPV and their oncoproteins, which could have an important impact on the management of HPV-associated cancers including cervical.

17 April 2014 in BMC Public Health
Verified
Journal Article
Open access
PDF file
OAOmar A Al-Farsi
Omar A Al-Farsi
YAYahya Al-Farsi
Yahya Al-Farsi
IGIshita Gupta
Ishita Gupta
AOAllal Ouhtit
Allal Ouhtit
KAKhalil S Al-Farsi
Khalil S Al-Farsi
Samir Al-AdawiSamir Al-Adawi
Samir Al-Adawi
Despite that hereditary diseases are widespread among the Arab population due to high rates of consanguineous marriages, research regarding community awareness towards premarital carrier screening in some countries such as Oman, is extremely scarce. This study aimed to investigate knowledge and attitude towards premarital carrier screening (PMCS) in Oman.